The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Abstract
BACKGROUND: The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied. METHODS: We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer. RESULTS: Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture. CONCLUSIONS: Androgen-deprivation therapy for prostate cancer increases the risk of fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Research works printed but not linked: 6
- Huggins C, 1941, Cancer Res, 1, 293
- 10.1111/j.1532-5415.2004.52029.x · doi:10.1111/j.1532-5415.2004.52029.x
- 10.1016/S0090-4295(02)01964-7 · doi:10.1016/s0090-4295(02)01964-7
- Warren JL, 2002, Med Care, 40, 3
- Prostate cancer. In: Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven,1997:219-22.
- Virnig BA, 2002, Med Care, 40, 49
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970
Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Billiet, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70223-0 · Cited by 946
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Roach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Warde, P., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R., Gospodarowicz, M., Sanders, K., Kostashuk, E., Swanson, G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61095-7 · Cited by 579
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig, H. C., Lam, C., Maltz, A., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00375 · Cited by 573
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70063-8 · Cited by 450
Goldin, G. H. (2012) · JAMA · doi:10.1001/jama.2012.460 · Cited by 445
Outcomes of Localized Prostate Cancer Following Conservative Management
Lu-Yao, G. L. (2009) · JAMA · doi:10.1001/jama.2009.1348 · Cited by 430
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Zumsteg, Z. S., Spratt, D. E., Pei, I., Zhang, Z., Yamada, Y., Kollmeier, M., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.033 · Cited by 397
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 375
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 355
Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9539 · Cited by 363
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
Shahinian, V. B., Kuo, Y., Freeman, J. L., Orihuela, E., & Goodwin, J. S. (2005) · Cancer · doi:10.1002/cncr.20955 · Cited by 323
Self-citationSurvival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Lu-Yao, G. L. (2008) · JAMA · doi:10.1001/jama.300.2.173 · Cited by 315
Greenspan, S. L., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00006 · Cited by 302
Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
GALVÃO, D. A., NOSAKA, K., TAAFFE, D. R., SPRY, N., KRISTJANSON, L. J., MCGUIGAN, M. R., SUZUKI, K., YAMAYA, K., & NEWTON, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
Cormie, P., Galvão, D. A., Spry, N., Joseph, D., Chee, R., Taaffe, D. R., Chambers, S. K., & Newton, R. U. (2015) · BJU International · doi:10.1111/bju.12646 · Cited by 277
Castration-Resistant Prostate Cancer: AUA Guideline
Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., Lin, D. W., Lowrance, W. T., Murad, M. H., Oh, W. K., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.005 · Cited by 275
Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer
Galvão, D. A., Spry, N. A., Taaffe, D. R., Newton, R. U., Stanley, J., Shannon, T., Rowling, C., & Prince, R. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07539.x · Cited by 270
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 266
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
Lowrance, W. T., Breau, R. H., Chou, R., Chapin, B. F., Crispino, T., Dreicer, R., Jarrard, D. F., Kibel, A. S., Morgan, T. M., Morgans, A. K., et al. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001375 · Cited by 265
Raisz, L. G. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042092 · Cited by 262
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3752 · Cited by 261
Droz, J., Balducci, L., Bolla, M., Emberton, M., Fitzpatrick, J. M., Joniau, S., Kattan, M. W., Monfardini, S., Moul, J. W., Naeim, A., et al. (2010) · BJU International · doi:10.1111/j.1464-410x.2010.09334.x · Cited by 258
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
“Although two of three studies examined subjects who nderwent orchiectomy exclusively [100,102], the largest n= 50,613) and most recent study included men who were sing LHRH agonists [101].”
BackgroundInfluentialPersonalised cancer follow-up: risk stratification, needs assessment or both?
Watson, E. K., Rose, P. W., Neal, R. D., Hulbert-Williams, N., Donnelly, P., Hubbard, G., Elliott, J., Campbell, C., Weller, D., & Wilkinson, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.535 · Cited by 106
Uth, J., Hornstrup, T., Christensen, J. F., Christensen, K. B., Jørgensen, N. R., Schmidt, J. F., Brasso, K., Jakobsen, M. D., Sundstrup, E., Andersen, L. L., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3399-0 · Cited by 84
The relationship between bone mineral density and fracture risk
McClung, M. R. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0005-y · Cited by 77
Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Darwish-Yassine, M., Berenji, M., Wing, D., Copeland, G., Demers, R. Y., Garlinghouse, C., Fagerlin, A., Newth, G. E., Northouse, L., Holmes-Rovner, M., et al. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-013-0312-8 · Cited by 55
Ethical and medical considerations of androgen deprivation treatment of sex offenders
Gooren, L. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1540 · Cited by 39
Gillessen, S., Murphy, L., James, N. D., Sachdeva, A., El-Taji, O., Abdel-Aty, H., Adler, A. I., Amos, C., Attard, G., Varughese, M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00231-1 · Cited by 28
Tombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2017.08.103 · Cited by 26
Deka, R., Rose, B. S., Bryant, A. K., Sarkar, R. R., Nalawade, V., McKay, R., Murphy, J. D., & Simpson, D. R. (2019) · Cancer · doi:10.1002/cncr.31982 · Cited by 23
Rocha-Rodrigues, S., Matos, A., Afonso, J., Mendes-Ferreira, M., Abade, E., Teixeira, E., Silva, B., Murawska-Ciałowicz, E., Oliveira, M. J., & Ribeiro, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094469 · Cited by 17
Metadata
- Authors
- Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-01-13
- Volume
- 352
- Issue
- 2
- Pages
- 154-164
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1997732940
- Cited by
- 1,375
- References
- 32
- FWCI
- 70.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.